2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P5318A
    MDYYFEER TFA 98%
    MDYYFEER TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MDYYFEER TFA has high DPPH and ABTS radical scavenging ability. MDYYFEER TFA protects zebrafish larvae from H2O2-induced oxidative damage.
    MDYYFEER TFA
  • HY-P5345A
    KLA peptide acetate
    KLA peptide (acetate) a cationic amphipathic mitochondrial membrane disrupting peptide that induces cell apoptosis by disrupting mitochondrial membrane. KLA peptide (acetate) can be used for the researches of cancer, inflammation, and neurological disease.
    KLA peptide acetate
  • HY-P5743A
    IRGRILHDGAYSLTLQGLGIH TFA 98%
    IRGRILHDGAYSLTLQGLGIH TFA is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH TFA can be used for the research class II HER2-DC1 vaccine studies.
    IRGRILHDGAYSLTLQGLGIH TFA
  • HY-P5744A
    SPPHPSPAFSPAFDNLYYWDQ TFA 98%
    SPPHPSPAFSPAFDNLYYWDQ TFA is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ TFA can be used for the research class II HER2-DC1 vaccine studies.
    SPPHPSPAFSPAFDNLYYWDQ TFA
  • HY-P5762A
    Phoenixin-14 TFA 98%
    Phoenixin-14 (PNX-14) TFA, a neuropeptide, has anxiolytic, cardioprotective and neuroprotective effect. Phoenixin-14 TFA can regulate pituitary gonadotrophin secretion by upregulating the GnRH receptor mRNA. Phoenixin-14 TFA stimulates insulin secretion. Phoenixin-14 TFA also protects mice from ischemia/reperfusion (IR) injury. PNX-14 TFA prevents oxidative stress by reducing ROS and increasing GSH.
    Phoenixin-14 TFA
  • HY-P5890A
    YVAD-CHO TFA
    YVAD-CHO TFA is an interleukin-1β converting enzyme (ICE, caspase 1) inhibitor (Ki: 0.76 nM). YVAD-CHO TFA inhibits mature IL-1β production. YVAD-CHO TFA partially delays motoneurone death in lesioned facial nerve mice.
    YVAD-CHO TFA
  • HY-P99436
    Anatumomab mafenatox 1370261-50-9
    Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness.
    Anatumomab mafenatox
  • HY-P99442
    Apolizumab 267227-08-7
    Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro.
    Apolizumab
  • HY-P99457
    Balstilimab 2148321-77-9 ≥99.0%
    Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1.
    Balstilimab
  • HY-P99478
    Bifarcept 163796-60-9
    Bifarcept is an interferon receptor type I (IFN-RI) fusion protein. Bifarcept can bind interferon receptors and prolong its serum half-life.
    Bifarcept
  • HY-P99495
    Cedelizumab 156586-90-2
    Cedelizumab (RWJ 49004) is a IgG4 monoclonal antibody targeting CD4. Cedelizumab has immunosuppressant properties.
    Cedelizumab
  • HY-P99525
    Varisacumab 1610010-60-0
    Varisacumab (R 84) is an antibody. Varisacumab can be used for various biochemical studies
    Varisacumab
  • HY-P99526
    Vapaliximab 336801-86-6
    Vapaliximab (2D10) is a monoclonal antibody against human VAP-1.
    Vapaliximab
  • HY-P99692
    Lenercept 156679-34-4
    Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1.
    Lenercept
  • HY-P99726
    Maslimomab 127757-92-0
    Maslimomab is a murine monoclonal antibody targeting T-cell receptor. Maslimomab is an immunosuppressive agent.
    Maslimomab
  • HY-P99745
    Morolimumab 202833-07-6
    Morolimumab is an IgG1 human anti-RHD/CD240D monoclonal antibody. Morolimumab can be used for the research of immune disease.
    Morolimumab
  • HY-P99771
    Onercept 199685-57-9
    Onercept is a recombinant soluble human tumor necrosis factor-alpha p55 receptor for use in Crohn's disease research.
    Onercept
  • HY-P99790
    Priliximab 147191-91-1
    Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4+ T cells. Priliximab can be used in research of rheumatoid arthritis (RA).
    Priliximab
  • HY-P9987A
    Crizanlizumab (anti-P-selectin) 1690318-25-2 98%
    Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
    Crizanlizumab (anti-P-selectin)
  • HY-P99929
    Enuzovimab 2531098-91-4
    Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity.
    Enuzovimab
Cat. No. Product Name / Synonyms Application Reactivity